Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Strand Expand Scope of GeneSpring Applications

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies and Strand Scientific Intelligence today announced an agreement to expand the scope of Agilent's GeneSpring bioinformatics system.

The agreement will increase utility of GeneSpring across multiple life science disciplines, drive future innovations, and "deliver new channels for accessing the software and customer support," the two companies said in a joint statement.

The agreement is expected to initially result in a version of GeneSpring that will allow researchers to do statistical analyses of and visualize data from genomic, metabolomics, and proteomics together "for the first time, using a familiar interface," they said. Strand's technology will be leveraged to enable integrated next-generation sequencing analysis abilities for GeneSpring users, they added.

As part of the agreement, a fully integrated portal for licensing, upgrading, and supporting the GeneSpring family of bioinformatics systems will be developed.

Agilent and Strand have worked together since August 2007. At the time Strand was developing Stratagene's ArrayAssist software. After Agilent acquired Stratagene, Agilent's GeneSping GX for gene expression was migrated to Strand's Avadis platform. All versions of GeneSpring have since been based on Avadis.

Francois Mandeville, Strand executive vice president, said in a statement, "Developing new scientific intelligence solutions that enable scientists to integrate, model, and visualize biological information is an important part of this new agreement, and we also look forward to going beyond this, developing new ways to deliver, customize, and support these solutions."

Financial terms of the deal were not announced.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.